p53 Accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type

Annals of Surgical Oncology

Volumn 6, Issue 8, 1999, Pages 739-745

  Roviello, Franco ^a   Marrelli, Daniele ^a   Vindigni, Carla ^a   De Stefano, Alfonso ^a   Spina, Donatella ^a   Pinto, Enrico ^a  

^a NONE

Author keywords

Gastric cancer; Immunohistochemistry; Intestinal diffuse histotype; Multivariate analysis; P53; Prognostic factors

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL TIME;

EID: 0033378195     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0739-3     Document Type: Article

References (39)

1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-107.
2. Pinto E, Roviello F, De Stefano A, Vindigni C. Early gastric cancer: report on 142 cases observed over 13 years. Jpn J Clin Oncol 1994;24:12-9.
3. Akoh JA, Macintyre IMC. Improving survival in gastric cancer review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293-9.
4. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
5. Lauren P, Nevalainen T. Epidemiology of intestinal and diffuse types of gastric carcinoma: a time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer 1993;71:2926-33.
6. Amorosi A, Bianchi S, Buiatti E, Cipriani F, Palli D, Zampi G. Gastric cancer in a high-risk area in Italy: histopathologic patterns according to Lauren's classification. Cancer 1988;62:2191-6.
7. Ireland A, Clark GW, DeMeester T. Barrett's esophagus: the significance of p53 in clinical practice. Ann Surg 1997;225:17-30.
8. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;5:1699-703.
9. Manne U, Myers RB, Moron C, et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997;74:346-58.
10. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
11. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
12. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997;80: 1034-45.
13. Passlick B, Izbicki JR, Haussinger K, Thetter O, Pantel K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995;109:1205-11.
14. Poller DN, Baxter KJ, Sheperd NA. p53, and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997;75:87-93.
15. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859-62.
16. Joypaul BV, Hopwood D, Newman EL, et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:543-6.
17. Starzynska T, Markiewski M, Domagala W, et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996;77:2005-12.
18. Ichiyoshi Y, Oiwa H, Tomisaki S, et al. Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 1997;44:546-53.
19. Motojima K, Furui J, Kohara N, Ito T, Kanematsu T. Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 1994;116:890-5.
20. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 1996;32:215-20.
21. Muller W, Borchard F. Prognostic influence of p53 expression in gastric cancer. J Pathol 1996;178:255-8.
22. Monig SP, Eidt S, Zirbes TK, Stippel D, Baldus SE, Pichlmaier H. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci 1997;42:2463-7.
23. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6.
24. Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/ sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-72.
25. Wu MS, Shun CT, Wang HP, et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997;112:1457-65.
26. Tahara E. Genetic alterations in human gastrointestinal cancers. Cancer 1995;75:1410-7.
27. Hermanek P, Sobin LJ. UICC TNM Classification of Malignant Tumors. 4th ed. and 2nd rev. Berlin: Springer-Verlag, 1992.
28. waf1/cip1 proteins gastric and esophageal cancers: comparison with mutations of the p53 gene. Dig Dis Sci 1998;43:279-89.
29. Ranzani GN, Luinetti O, Padovan LS, et al. p53 gene mutations and protein nuclear accumulation are early events in the intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 1995;4:223-31.
30. Hong SIL, Hong WS, Jang JJ. et al. Alterations of p53 gene in primary gastric cancer tissue. Anticancer Res 1994;14:1251-5.
31. Lim BHG, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 1996;69: 200-4.
32. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
33. Craanen ME, Blok P, Dekker W, Offerhaus GJA, Tytgat GNJ. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995;36:848-52.
34. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S. p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993;54:759-64.
35. Lee WJ, Shun CT, Hong RL, Wu MS, Chan KJ, Chen KM. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg 1998;85:1138-42.
36. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 1998;43:964-70.
37. Fonseca L, Yonemura Y, De Aretxabala X, Yamaguchi A, Miwa K, Miyazaki I. p53 detection as a prognostic factor in early gastric cancer. Oncology 1994;51:485-90.
38. Buonsanti G, Calistri D, Padovan L, et al. Microsatellite instability in intestinal- and diffuse-type gastric carcinoma. J Pathol 1997; 182:167-73.
39. Vollmers HP, Dammrich J, Hensel F, et al. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 1997;79:433-40.